Outpatient initiation of direct-to-inject buprenorphine
Open Access
- 19 December 2025
- journal article
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 278, 113011
Abstract
No abstract availableKeywords
Funding Information
- National Institute on Drug Abuse (K23DA060329)
- National Institute on Alcohol Abuse and Alcoholism (R25DA033211)
This publication has 19 references indexed in Scilit:
- High-Dose Buprenorphine Treatment in the Setting of FentanylJAMA Network Open, 2025
- Retention and dropout from sublingual and extended-release buprenorphine treatment: A comparative analysis of data from a nationally representative sample of commercially-insured people with opioid use disorder in the United StatesInternational Journal of Drug Policy, 2025
- Outpatient Low-Dose Initiation of Buprenorphine for People Using FentanylJAMA Network Open, 2025
- Buprenorphine-Precipitated Withdrawal Among Hospitalized Patients Using FentanylJAMA Network Open, 2024
- Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid WithdrawalJAMA Network Open, 2024
- Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of FentanylJAMA Network Open, 2023
- A Neuropharmacological Model to Explain Buprenorphine Induction ChallengesAnnals of Emergency Medicine, 2022
- The Pharmacology of Buprenorphine Microinduction for Opioid Use DisorderClinical Drug Investigation, 2021
- Protracted renal clearance of fentanyl in persons with opioid use disorderDrug and Alcohol Dependence, 2020
- Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use DisorderDrugs in R&D, 2019